Description

Nurix Therapeutics, Inc., a biopharmaceutical firm headquartered in San Francisco, California, was founded in 2009. This company, which rebranded from Nurix Inc. in October 2018, is dedicated to the identification, advancement, and commercialization of innovative small molecule treatments for various cancers and immune system disorders. Its robust pipeline features several key drug candidates: NX-2127 and NX-5948: Both are orally administered Bruton's tyrosine kinase (BTK) degraders, targeting B-cell malignancies that have relapsed or are resistant to prior therapies. NX-5948 is also being explored for autoimmune conditions. NX-1607: An orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, developed for immuno-oncology applications. NX-0255: A CBL-B inhibitor designed for ex vivo use to enhance the efficacy of adoptive T-cell therapies. DeTIL-0255: Currently undergoing Phase 1 clinical trials for gynecological cancers, including ovarian, endometrial, and cervical cancers. To further its mission, Nurix has forged significant strategic alliances, notably with Gilead Sciences, Inc. for the development of therapies addressing cancer and other challenging diseases, and also with Sanofi S.A.